Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Nasdaq100 ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Nasdaq100 ETF trades at $751.85 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 40.3× Halozyme Therapeutics Inc. Common Stock's market cap, and Nasdaq100 ETF is more actively traded (48,326,518 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Nasdaq100 ETF for 162 Days on average.
| HALO | QQQ | |
|---|---|---|
Market Cap | $12.58B | $506.92B |
Volume | 2,179,278 | 48,326,518 |
Sector | Health | — |
52-Week High | $115.22 | $759.66 |
52-Week Low | $61.63 | $558.34 |
Typical Hold Time | 1 Days | 162 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQ trades at $750.47, down 0.96% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights QQQ's strong 10-year performance and ongoing innovation with new fund launches, though concerns about AI market valuations and interest rate impacts create headwinds.
The outlook remains cautiously optimistic given QQQ's tech-heavy exposure to AI growth trends, but elevated valuations and macroeconomic sensitivity present near-term risks. Long-term growth potential persists through innovation leadership, though investors should monitor concentration risk in technology holdings and market volatility around Fed policy decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
